|
Gene: FBXW2 |
Gene summary for FBXW2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | FBXW2 | Gene ID | 26190 |
Gene name | F-box and WD repeat domain containing 2 | |
Gene Alias | FBW2 | |
Cytomap | 9q33.2 | |
Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q9UKT8 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
26190 | FBXW2 | LZE4T | Human | Esophagus | ESCC | 1.42e-13 | 2.12e-01 | 0.0811 |
26190 | FBXW2 | LZE7T | Human | Esophagus | ESCC | 1.71e-08 | 3.07e-01 | 0.0667 |
26190 | FBXW2 | LZE8T | Human | Esophagus | ESCC | 1.83e-04 | 1.41e-01 | 0.067 |
26190 | FBXW2 | LZE20T | Human | Esophagus | ESCC | 2.63e-08 | 2.85e-01 | 0.0662 |
26190 | FBXW2 | LZE24T | Human | Esophagus | ESCC | 9.88e-15 | 3.38e-01 | 0.0596 |
26190 | FBXW2 | LZE21T | Human | Esophagus | ESCC | 1.65e-05 | 1.53e-01 | 0.0655 |
26190 | FBXW2 | LZE6T | Human | Esophagus | ESCC | 7.87e-04 | 2.87e-01 | 0.0845 |
26190 | FBXW2 | P1T-E | Human | Esophagus | ESCC | 1.66e-07 | 2.75e-01 | 0.0875 |
26190 | FBXW2 | P2T-E | Human | Esophagus | ESCC | 4.34e-22 | 4.88e-01 | 0.1177 |
26190 | FBXW2 | P4T-E | Human | Esophagus | ESCC | 3.78e-24 | 4.21e-01 | 0.1323 |
26190 | FBXW2 | P5T-E | Human | Esophagus | ESCC | 5.11e-09 | 1.16e-01 | 0.1327 |
26190 | FBXW2 | P8T-E | Human | Esophagus | ESCC | 3.50e-15 | 3.05e-01 | 0.0889 |
26190 | FBXW2 | P9T-E | Human | Esophagus | ESCC | 1.32e-13 | 2.95e-01 | 0.1131 |
26190 | FBXW2 | P10T-E | Human | Esophagus | ESCC | 8.99e-16 | 2.68e-01 | 0.116 |
26190 | FBXW2 | P11T-E | Human | Esophagus | ESCC | 3.09e-15 | 5.50e-01 | 0.1426 |
26190 | FBXW2 | P12T-E | Human | Esophagus | ESCC | 1.02e-14 | 3.45e-01 | 0.1122 |
26190 | FBXW2 | P15T-E | Human | Esophagus | ESCC | 1.61e-27 | 4.42e-01 | 0.1149 |
26190 | FBXW2 | P16T-E | Human | Esophagus | ESCC | 2.58e-23 | 3.35e-01 | 0.1153 |
26190 | FBXW2 | P17T-E | Human | Esophagus | ESCC | 5.36e-11 | 3.46e-01 | 0.1278 |
26190 | FBXW2 | P19T-E | Human | Esophagus | ESCC | 4.76e-04 | 3.95e-01 | 0.1662 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Esophagus | ESCC | |
Skin | AK | |
Skin | SCCIS | |
Skin | cSCC | |
Thyroid | HT |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FBXW2 | SNV | Missense_Mutation | c.1028C>T | p.Ser343Leu | p.S343L | Q9UKT8 | protein_coding | deleterious(0) | probably_damaging(0.95) | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
FBXW2 | SNV | Missense_Mutation | c.1171N>A | p.Asp391Asn | p.D391N | Q9UKT8 | protein_coding | tolerated(0.38) | probably_damaging(0.977) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
FBXW2 | SNV | Missense_Mutation | c.889N>A | p.Asp297Asn | p.D297N | Q9UKT8 | protein_coding | tolerated(0.14) | probably_damaging(0.956) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
FBXW2 | SNV | Missense_Mutation | c.251C>G | p.Ser84Cys | p.S84C | Q9UKT8 | protein_coding | tolerated(0.33) | benign(0) | TCGA-E2-A15M-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
FBXW2 | SNV | Missense_Mutation | novel | c.476N>A | p.Gly159Glu | p.G159E | Q9UKT8 | protein_coding | tolerated(0.2) | probably_damaging(0.999) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
FBXW2 | SNV | Missense_Mutation | c.997C>T | p.His333Tyr | p.H333Y | Q9UKT8 | protein_coding | deleterious(0.01) | benign(0.069) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
FBXW2 | SNV | Missense_Mutation | c.753N>C | p.Lys251Asn | p.K251N | Q9UKT8 | protein_coding | deleterious(0.04) | probably_damaging(0.995) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
FBXW2 | SNV | Missense_Mutation | c.739G>T | p.Asp247Tyr | p.D247Y | Q9UKT8 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
FBXW2 | SNV | Missense_Mutation | c.8G>T | p.Arg3Ile | p.R3I | Q9UKT8 | protein_coding | tolerated_low_confidence(0.06) | benign(0.029) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
FBXW2 | SNV | Missense_Mutation | c.863C>A | p.Pro288His | p.P288H | Q9UKT8 | protein_coding | tolerated(0.05) | probably_damaging(0.99) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |